



CITURGIA BIOCHEMICALS LIMITED

Regd. Office: 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,
Bhayandar, East, Thane-401105, Maharashtra, CIN: L24100MH1974PLC017773

Website: www.citurgiabio.com; E-mail id: citurgia_bio@yahoo.com

Date: 21.10.2023

To,

**BSE Limited
P J Towers, Dalal Street
Mumbai – 400001
Scrip Code: 506373,
Scrip ID: CITURGIA**

Sub: Submission of Unaudited Financial Results for Quarter ended 30th June, 2023.

Dear Sir/Madam,

Please find enclosed herewith Unaudited Financial Results for the Quarter ended 30th June, 2023 along with Limited Review Report issued by the statutory auditor for the quarter ended 30th June, 2023 as approved by the Board of Directors in their meeting held on 14th August, 2023.

Please take the above information on record.

FOR CITURGIA BIOCHEMICALS LIMITED


KASHI NATH
WHOLE TIME DIRECTOR

Din No. 02072952

Statement of Unaudited Financial Results for the quarter ended 30.06.2023

Amount in Lakh

Particulars		Quarter Ended			Year Ended
		3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Previous Year Ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I.	Total Income from Operations	-	-	-	-
II.	Other Income	-	-	-	-
III.	Total Revenue (I+II)	-	-	-	-
IV.	Expenses				
	a) Cost of Materials consumed	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, WIP and stock in trade	-	-	-	-
	d) Employee benefits expenses	3.00	4.40	3.00	16.20
	e) Depreciation and amortisation expenses	5.15	5.73	5.15	22.56
	f) Other expenses	0.94	4.33	0.20	4.86
	Total Expenses	9.09	14.46	8.34	43.62
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-V)	(9.09)	(14.46)	(8.34)	(43.62)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (VI-VII)	(9.09)	(14.46)	(8.34)	(43.62)
VIII	Extraordinary items	-	-	-	-
IX	Profit/(Loss) before tax (VIII-IX)	(9.09)	(14.46)	(8.34)	(43.62)
X	Tax expenses				
	a) Current Tax	-	-	-	-
	a) Income Tax Adjustment	-	-	-	-
	a) MAT Credit Entitlement	-	-	-	-
	b) Deferred Tax Liabilities / (Assets)	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(9.09)	(14.46)	(8.34)	(43.62)
XII	Profit/(loss) from discontinuing operations	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(9.09)	(14.46)	(8.34)	(43.62)
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive	(9.09)	(14.46)	(8.34)	(43.62)

	Income for the period)				
XVIII	Earnings per equity share (for continuing operation):				
	(1) Basic	(0.000)	(0.000)	(0.000)	(0.000)
	(2) Diluted	(0.000)	(0.000)	(0.000)	(0.000)
XIX	Earnings per equity share (for discontinued operation):				
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-
XX	Earning Per Share (for discontinued & continuing operations)				
	a) Basic	(0.000)	(0.000)	(0.000)	(0.000)
	b) Diluted	(0.000)	(0.000)	(0.000)	(0.000)

NOTES :


1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th August, 2023.

2. The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications.

3. The financial results are subject to the Limited Review Report issued by the statutory auditors of the company.

4. The Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules there under in terms of Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

FOR CITURGIA BIOCHEMICALS LIMITED


KASHI NATH
DIRECTOR
DIN No. 08092918

Date : 14.08.2023

Place : Mumbai